How to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation

سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 261

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IRJNM-25-1_007

تاریخ نمایه سازی: 21 بهمن 1398

چکیده مقاله:

Introduction:Differentiated thyroid carcinoma (DTC) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (Tg), diagnostic iodine-131 whole body scan (DxWBS) and sonography. Some patients with undetectable Tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. Methods: In this study, we enrolled DTC patients with undetectable Tg but small thyroid residue in six-month-DxWBS following first radioiodine-ablation. Patients with detectable Tg, high TgAb, suspicious neck lymphadenopathy in sonography and metastasis were excluded. Ninety four patients were placed in two groups of cohort, i.e., radioiodine-retreatment group (n=36) versus observation (untreated) group (n=58). After six months, the clinical outcome was compared by evaluating DxWBS, Tg, TgAb and sonography. Results: DxWBS showed sustained thyroid remnant in 47.2% of retreated patients while 34.5% of untreated group revealed negative DxWBS over the next period of follow-up. Also, only 6 cases (16.7%) in retreatment group and 12 cases (20.7%) in observation group revealed an additional finding other than local faint RAI uptake, including detectable serum Tg, rising TgAb or suspicious ultrasound finding, favoring no significant difference of the outcome as well as relative risk of new finding incidence between treated and untreated patients (CI 95% for relative risk: 0.58-2.41; p=0.630). Conclusion: Regarding sonologic and laboratory follow-up evidences, RAI-retreatment shows no significant advantage over observation in DTC patients with Tg negative, remnant positive DxWBS. In addition, residual thyroid tissue was completely disappeared in about one third of patients without retreatment.

نویسندگان

Babak Fallahi

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Armaghan Fard-Esfahani

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Alireza Emami-Ardekani

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Somayeh Sahari

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and ...
  • Francis GL, Waguespack SG, Bauer AJ Angelos P, Benvenga S, ...
  • Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, ...
  • Kloos RT. Thyroid cancer recurrence in patients clinically free of ...
  • Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, ...
  • Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, ...
  • Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC. ...
  • Lee JI, Chung YJ, Cho BY, Chong S, Seok JW, ...
  • Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, ...
  • Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, ...
  • Durante C, Montesano T, Attard M, Torlontano M, Monzani F, ...
  • Ma C, Kuang A, Xie J, Ma T. Possible explanations ...
  • Park EK, Chung JK, Lim IH, Park DJ, Lee DS, ...
  • Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, ...
  • Lim DJ, O JH, Kim MH, Kim JH, Kwon HS, ...
  • Kim EY, Kim WG, Kim WB, Kim TY, Ryu JS, ...
  • Silberstein EB. The treatment of thyroid malignant neoplasms. In: Henkin ...
  • Tuttle RM, Becker DV, Hurley JR. Radioiodine treatment of thyroid ...
  • Whitley RJ, Ain KB. Thyroglobulin: a specific serum marker for ...
  • Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, ...
  • Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, ...
  • Ciappuccini R, Hardouin J, Heutte N, Vaur D, Quak E, ...
  • Dai J, Dent W, Atkinson JW, Cox JG, Dembinski TC. ...
  • Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis ...
  • Feldt-Rasmussen U, Verburg FA, Luster M, Cupini C, Chiovato L, ...
  • Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, ...
  • Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) ...
  • Giovanella L, Suriano S, Ceriani L, Verburg FA. Undetectable thyroglobulin ...
  • Torréns JI, Burch HB. Serum thyroglobulin measurement. Utility in clinical ...
  • Lupoli GA, Okosieme OE, Evans C, Clark PM, Pickett AJ, ...
  • Gianoukakis AG. Thyroglobulin antibody status and differentiated thyroid cancer: what ...
  • Chung JK, Park YJ, Kim TY, So Y, Kim SK, ...
  • M El-Refaei S1, W Yassin S, Salman K, Al Munshy ...
  • Giovanella L, Piccardo A, Paone G, Foppiani L, Treglia G, ...
  • Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, ...
  • Kim EY, Kim TY, Kim WG, Yim JH, Han JM, ...
  • Du P, Jiao X, Zhou Y, Li Y, Kang S, ...
  • Bal C, Chandra P, Kumar A, Dwivedi S. A randomized ...
  • Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, ...
  • Cheng W, Ma C, Fu H, Li J, Chen S, ...
  • Valachis A, Nearchou A. High versus low radioiodine activity in ...
  • Rees GJ. Radioiodine ablation for differentiated thyroid cancer-none, one dose ...
  • Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, ...
  • Esfahani AF, Fallahi B, Olamaie R, Eftekhari M, Beiki D, ...
  • Esfahani AF, Eftekhari M, Zenooz N, Saghari M. Gonadal function ...
  • Fard-Esfahani A, Hadifar M, Fallahi B, Beiki D, Eftekhari M, ...
  • Fard-Esfahani A, Mirshekarpour H, Fallahi B, Eftekhari M, Saghari M, ...
  • Fard-Esfahani A, Farzanefar S, Fallahi B, Beiki D, Saghari M, ...
  • Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, ...
  • Phan HT, Jager PL, van der Wal JE, Sluiter WJ, ...
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, ...
  • نمایش کامل مراجع